Mission and Business model

Mission 
BACTherapy aims to test and realise the promise of bacterial immunotherapy as cancer treatment.

BACTherapy aims to validate the clinical utility of bacterial immunotherapy and then ensure its availability worldwide as a safe, effective and affordable cancer treatment.

Business model
Drug development is traditionally funded by the pharmaceutical industry or by venture capital.

Patent protection for new drugs is essential for them to be sold at prices that can generate a return on investment. Patent protection has thus enabled the development of many important innovative therapies.

Bacterial immunotherapeutics can be produced cheaply, are routinely used in the treatment of bladder cancer, and have previously been successfully tested for a variety of cancers.

As such, bacterial immunotherapeutics can no longer be patented in a manner that provides meaningful protection. This is likely the reason why pharmaceutical / venture capital industries are not investing in the further development of bacterial immunotherapy products.

There is academic interest in bacterial immunotherapy. The American National Cancer Institute has, for instance, recently provided grants for "Microbial-based Cancer Therapy - Bugs as Drugs” and leading scientific journals have published multiple articles on the promise of bacterial immunotherapy. However, academic institutes will not be producing and providing products after a publication shows evidence of efficacy.

BACTherapy thus seeks funding from organisations that are motivated to help provide efficacious & safe cancer treatment at low costs worldwide.  

BACTherapy will use this funding to carry out further research and clinical trials to validate the use of bacterial immunotherapy as an effective treatment. 

Once bacterial immunotherapies have been approved, BACTherapy will make these therapies available at sustainable affordable prices.  

Organisation
BACTherapy will be a lean organisation and implement and oversee the following tasks:

• Further research will be performed by members of the BACTherapy scientific board.
• Bacterial immunotherapy products will be manufactured, tested and distributed by contract research organisations & manufacturers.

BACTherapy will thus not need to invest in own infrastructure to achieve its mission.

Scientific excellence and a shared motivation to define and generate real products are key drivers for success. BACTherapy has thus established an excellent team of scientists and experts (see Team) that together will define and execute the steps towards achieving our shared goals.